Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 4/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | MLNR | O43193 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317404 | 0.95 | ALDH1A1 (0.40) | LMNAALDH1A1RAB9ATP53POLB | |
| SCHEMBL3313172 | 0.81 | PARP10 (0.46) | LMNAALDH1A1RAB9ACCR2 | |
| SCHEMBL3315505 | 0.78 | CCR2 (0.46) | CCR2 | |
| SCHEMBL3316461 | 0.77 | L3MBTL1 (0.41) | LTA4HEPHX2ALDH1A1POLBMLNR | |
| SCHEMBL3313736 | 0.77 | LTA4H (0.44) | LTA4HEPHX2LMNAALDH1A1RAB9A | |
| SCHEMBL3313789 | 0.76 | FAAH (0.46) | NPY5RLMNAALDH1A1RAB9ATPSAB1 | |
| SCHEMBL3317034 | 0.72 | CCR2 (0.45) | NPY5RCCR2 | |
| SCHEMBL3313029 | 0.69 | CCR2 (0.46) | CCR2 | |
| SCHEMBL3318035 | 0.69 | FAAH (0.53) | LTA4HLMNAALDH1A1RAB9APOLB | |
| SCHEMBL3317869 | 0.69 | HRH3 (0.47) | NPY5RLMNAALDH1A1RAB9ATPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | CCR3 919/4885LTA4H 642/4885EPHX2 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.